Public Citizen Opposes Approval of Drug with Liver Toxicity Risks at FDA Advisory Committee Meeting

View as PDF.

In testimony before the Food and Drug Administration, Public Citizen spoke against approval of the drug tolvaptan for use in polycystic kidney disease, citing its liver toxicity risks and that it does not meet essential elements of efficacy needed for drug approval.